Educated Patient® Breast Cancer Summit at MBCC: March 4, 2023 - Episode 1
Watch Dr. Anne O'Dea, from University of Kansas Medical Center, discuss targeting ESR1 mutations during the CURE Educated Patient® Breast Cancer Summit at MBCC.
At the CURE Educated Patient® Breast Cancer Summit, held live and virtually at the Miami Breast Cancer Conference, Dr. Anne O'Dea, medical director of breast cancer survivorship at the University of Kansas Medical Center, presented the keynote lecture, titled “A new era in the treatment of ER+, HER2- Advanced or Metastatic Breast Cancer: targeting ESR1 mutations.”
In particular, O’Dea discusses the need for new endocrine therapies to treat estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as well as results from the EMERAL trial, that led to the Food and Drug Administration approval of elacestrant (Orserdu) in this patient population.
Disclosure: O’Dea is a consultant and/or speaker for Gilead, DSI, Puma, Pfizer, Novartis and Stemline.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.